ALVO vs IRMD

ALVO's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates weak financial health, with poor profitability, negative operating margins, and erratic earnings. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, especially given negative operating margins and a low quick ratio of 0.54. Despite a modest 10.6% YoY revenue growth and a 55.59% gross margin, the company exhibits severe earnings instability, with a -161.1% YoY EPS decline and multiple quarters of massive negative surprises. The stock trades at a premium to its intrinsic value of $1.61, suggesting overvaluation based on current fundamentals. Analysts' target price of $18.83 appears disconnected from current performance and financial health.

IRMD presents a dichotomy between exceptional operational performance and extreme valuation premiums. While the Piotroski F-Score of 4/9 indicates stable financial health and the company boasts an impressive 76.75% gross margin and a consistent 25-quarter earnings beat record, the stock is trading significantly above its Graham Number ($17.07) and Intrinsic Value ($51.62). The strong fundamental growth is currently offset by bearish insider activity from the CEO and a completely bearish technical trend (0/100).